HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon VP

This article was originally published in The Rose Sheet

Executive Summary

Coca Cola exec Paul Murphy to exec VP-North American sales effective Feb. 1. Reporting to CEO Jack Stahl, Murphy will be responsible for sales management, customer management and business development operations for all Revlon products in North America, company says. Murphy joined Coca Cola in 1982, serving most recently as VP-national sales and VP-customer development. He started his career at Procter & Gamble. Exec will succeed Larry Aronson, who will leave Revlon after a transition period, company adds. Aronson was appointed to the post in 2000 under management of Jeffrey Nugent (1"The Rose Sheet" May 8, 2000, p. 4)...

You may also be interested in...



Revlon "Pulling" For Growth With Product Trial, Positioning Reassessment

Revlon will move toward a "pull" marketing strategy and away from a "push" initiative as part of a fundamental shift in marketing practices to help rebuild the company and retailer enthusiasm, Revlon CEO Jeffrey Nugent said.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel